IL6 and cancer: EOs showed significant cytotoxic effects on cancer cell lines (IC50 0.007 to >0.1%), with a reduction in cell viability with up to 90% at a concentration of 0.1%, and anti-inflammatory activity (IC50 0.0008–0.02%) with a reduction of IL-6 secretion with up to 60% at a concentration of 0.01%.